Clinical Question: Do patients above 70 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination?
Bottom Line: For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2016.2050 | DOI Listing |
Publication Analysis
Top Keywords
advanced non-small-cell
8
non-small-cell lung
8
lung cancer
8
elderly patients
8
platinum-based combination
8
chemotherapy advanced
4
cancer elderly
4
patients clinical
4
clinical question
4
question patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!